Cytometry. Part B, Clinical cytometry · 2014
CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mannelli Francesco, Cutini Ilaria, Gianfaldoni Giacomo, Bencini Sara, Scappini Barbara, Pancani Fabiana, Ponziani Vanessa, Bonetti Maria Ida, Biagiotti Caterina, Longo Giovanni, Bosi Alberto
Аннотация
BACKGROUND: In acute myeloid leukemia (AML), CXCR4 expression has been correlated with leukocytosis and prognosis.
METHODS: We quantified CXCR4 expression by flow cytometry on leukemic cells in 142 AML patients.
RESULTS: We confirm a correlation between high CXCR4 expression and leukemic burden. Furthermore, we documented a correlation with platelet count, dysplastic megakaryopoiesis, hepato-splenomegaly and extra-hematological disease. NPM1-mutated AML displayed a significantly higher intensity of CXCR4 compared to NPM1-wt cases: it is conceivable its clinical phenotype to be driven by high CXCR4 expression.
CONCLUSIONS: CXCR4 expression resulted in an independent prognostic factor. Our data support CXCR4 targeting as a potential therapeutic strategy.
METHODS: We quantified CXCR4 expression by flow cytometry on leukemic cells in 142 AML patients.
RESULTS: We confirm a correlation between high CXCR4 expression and leukemic burden. Furthermore, we documented a correlation with platelet count, dysplastic megakaryopoiesis, hepato-splenomegaly and extra-hematological disease. NPM1-mutated AML displayed a significantly higher intensity of CXCR4 compared to NPM1-wt cases: it is conceivable its clinical phenotype to be driven by high CXCR4 expression.
CONCLUSIONS: CXCR4 expression resulted in an independent prognostic factor. Our data support CXCR4 targeting as a potential therapeutic strategy.